We hypothesized that RhoBTB2 might partly mediate the membrane trafficking and distribution of chemotherapeutic drugs and thus contribute to the poor outcomes of AML treatment, but the in-depth mechanism requires more laboratory work. This evidence concerns the gene RHOBTB2 and acute myeloid leukemia.